Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). No substantive Regulation FD disclosure provided in the excerpt.
Tonix Pharmaceuticals Holding Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- No substantive Regulation FD disclosure provided in the excerpt
- Investor impact cannot be assessed without the referenced disclosure or exhibit content
Item 8.01 · Other Events
- HORIZON Study enrollment initiated with first participant on June 29, 2026
- Clinical milestone advances Tonix’s development program into participant testing
- Investor focus shifts to enrollment pace, trial data, and potential regulatory catalysts
Item EX-99.1 · Exhibit EX-99.1
- First patient enrolled in HORIZON, initiating a potentially pivotal Phase 2 MDD study for TNX-102 SL
- Approximately 360 adults targeted across approximately 30 U.S. sites
- Six-week trial’s primary endpoint: MADRS score change from baseline at Week 6
- Existing FDA approval and TONMYA commercial launch in fibromyalgia provide a clinical and commercial platform
- MDD indication remains investigational, with efficacy and safety not established by regulators
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tonix Pharmaceuticals Holding Corp. 8-K filings
Get the next TNXP 8-K as it lands
Follow TNXP for push alerts, or ask the research agent what this filing means.